US clinical stage biotech Rapport Therapeutics (Nasdaq: RAPP) has announced the appointment of Dr Jeffrey Sevigny as chief ...

Dr. Sevigny joins Rapport following his tenure as chief medical officer at Prevail Therapeutics See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...

Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson's, in a deal potentially worth more than $1 billion. The big US pharma is to ...

The Medtronic Prevail drug coated balloon [Image courtesy of Medtronic] Medtronic (NYSE: MDT) + announced results from a ...

Dr. Sevigny, a seasoned leader in drug development, brings over 15 years of experience to the role, having previously served as CMO at Prevail Therapeutics (NASDAQ:PRVL) and senior vice president ...